**S5 Table. Odds of detectable plasma viral load for women using ART or difference in mean change of log10 pVL among women not using ART at enrolment, comparing women using the levonorgestrel intrauterine system (LNG-IUS) with those using the copper T-380 intrauterine device (C-IUD), with linear regression adjusted by visit month, among women living with HIV in Cape Town, South Africa**

|  | **Detectable pVL by study visitART-using women(n= 132)** | **Change of log10 pVL across 6- or 24-month visit Non-ART women(n= 67)** |
| --- | --- | --- |
|  | **OR (95% CI)** | **Difference (95% CI)** |
| **As-treated analysis** |  |  |
| Across 6 months (covariate set #1) | 0·80 (0·35–1·80) |  |
| Across 6 months (covariate set #2) |  | -0·09 (-0·29–0·11) |
| Across 24 months (covariate set #1) | 0·90 (0·46–1·74) |  |
| Across 24 months (covariate set #2) |  | -0·02 (-0·38–0·34) |
| **Intent-to-treat analysis** |  |  |
| Across 6 months (covariate set #1) | 0·81 (0·36–1·83) |  |
| Across 6 months (covariate set #2) |  | -0·07 (-0·26–0·11) |
| Across 24 months (covariate set #1) | 0·90 (0·46–1·73) |  |
| Across 24 months (covariate set #2) |  | 0·03 (-0·31–0·36) |
| **Adjusted As-treated analysis** |  |  |
| Across 6 months (covariate set #3) | 0·80 (0·35–1·82) |  |
| Across 6 months (covariate set #4) |  | -0·11 (-0·30–0·09) |
| Across 24 months (covariate set #3) | 0·91 (0·47–1·76) |  |
| Across 24 months (covariate set #4) |  | -0·03 (-0·38–0·33) |
| ART=antiretroviral therapy; CI=confidence interval; n=number; OR=odds ratio; pVL=plasma viral load. RTI=reproductive tract infection. Covariate set #1: Baseline detectable pVL, age, and visit month.Covariate set #2: Baseline continuous pVL (log 10 continuous), age, and visit month.Covariate set #3: Baseline detectable pVL, any RTI, age, and visit month.Covariate set #4: Baseline continuous pVL (log 10 continuous), any RTI, age, and visit month.  |